Leviticus Cardio is developing a wireless system able to provide the day-to-day power needs of VAD implants while eliminating the complications related to the drive line.
The Company’s solution uses a proprietary technology, Coplanar Energy Transfer (CET), that works with available commercial LVADs, including market-leading HM3 (HeartMate) and HVAD® (HeartWare). The innovative CET system provides effective transcutaneous energy transfer with important advantages over competing wireless energy transfer technologies —
Trendlines’ director: Steve Rhodes
Stage: Business development
Investors: Raised $8.7 million (as at 25 April 2018); The Trendlines Group, Maryland/Israel Trendlines Fund, MDs and VAD expert group, Israel’s Office of the Chief Scientist grants
IP: 12 issued patents and 2 pending (United States)
Thousands of patients each year are candidates for heart transplantation. An alternative to heart transplantation is the ventricular assist device (VAD), an implanted mechanical circulatory pump that is increasingly being used to support patients with heart failure.
To supply power to the pump, the VAD is connected to an external power pack by a transcutaneous drive line. The exit site of the drive line on the abdomen provides a port of entry for pathogens, making VAD recipients highly vulnerable to device-related infections. Infection and reduction in quality of life (both related to the drive line) represent the most important challenge to extended VAD use.
According to Grand View Research, the global LVAD market was valued at US$763 million in 2014 and is set to grow to US$1.98 billion by 2022, driven by increased prevalence of cardiovascular disease, advances in technology, and favorable reimbursement, among other factors.*
Leviticus estimates the TAM for its CET system at $900 million. Players in the VAD market include St. Jude Medical, HeartWare, Jarvik Heart, Cleveland Heart, Sunshine Heart, CorWave, Rein VAD (AME), Calon Cardio, Berlin Heart, and Relight Heart.
*Congestive Heart Failure (CHF) Treatment Devices Market Analysis by Product (Ventricular Assist Devices, Counter Pulsation Devices, Implantable Cardioverter Defibrillators, Pacemakers, Cardiac Resynchronization Therapy) And Segment Forecasts to 2024. Grand View Research, October 2016.
See the company one-page description in Chinese (PDF).
Michael Zilbershlag presents at Trendlines Medical Asia Road Show.
See an animation of the Leviticus Cardio system.
Michael Zilbershlag presents at a Trendlines Showcase.
Minimally invasive treatment of heart valve disease
A more efficient ablation catheter to treat atrial fibrillation
Preventing the development of pressure sores
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer